DBV Technologies

DBV Technologies is a late-stage specialty biopharmaceutical company developing treatments for food allergies and other immunologic conditions. Its proprietary VIASKIN patch platform delivers epicutaneous immunotherapy (EPIT), a non-invasive approach that applies microgram amounts of a biologically active allergen to intact skin. The aim is to desensitize the immune system by using the skin's immune-tolerizing properties. The lead candidate, VIASKIN Peanut Patch, is under development for peanut allergy in two groups: children aged 4 through 7 and toddlers aged 1 through 3. A BLA for children aged 4 through 7 was submitted to the U.S. FDA in September 2026, supported by the 654-patient Phase 3 VITESSE trial. A toddler BLA is expected in 2027, and the COMFORT Toddlers and THRIVE studies continue. The company is building U.S. commercial infrastructure across sales, market access, marketing and pharmacovigilance ahead of a potential launch. It relies on contract manufacturer Fareva Amboise for patch production. DBV has no product revenue; its operating income consists of French Research Tax Credits. The company funds its operations through equity financings, including an ATM program. Its ordinary shares trade on Euronext Paris (DBV), and its ADSs, each representing five ordinary shares, trade on the Nasdaq Capital Market (DBVT). Updated Oct 28, 2026